Sara Giuliano

Dr. Sara Giuliano

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2025 in American Journal of Reproductive Immunology
Verified
Journal Article
Closed access
SILVIA D'IPPOLITOSILVIA D'IPPOLITO
SILVIA D'IPPOLITO
FGFilippo Gavi
Filippo Gavi
CGChiara Granieri
Chiara Granieri
CWChiara De Waure
Chiara De Waure
Sara GiulianoSara Giuliano
Sara Giuliano
Nicoletta Di SimoneNicoletta Di Simone
Nicoletta Di Simone

1 November 2023 in Minerva Pediatrics
Verified
Journal Article
Closed access
CCClelia Cipolla
Clelia Cipolla
Giorgio SoderoGiorgio Sodero
Giorgio Sodero
ICIgnazio Cammisa
Ignazio Cammisa
ACArianna Turriziani Colonna
Arianna Turriziani Colonna
Sara GiulianoSara Giuliano
Sara Giuliano
PVPaola Villa
Paola Villa
Article: The impact of glucocorticoids on bone health and growth: endocrine and non-endocrine effects in children and young patients - Minerva Pediatrics 2022 Oct 31 - Minerva Medica - Journals

30 October 2025 in Cureus
Verified
Journal Article
Open access
PDF file
Sara GiulianoSara Giuliano
Sara Giuliano
DRDaniela Ruiz
Daniela Ruiz
NBNidhi Basavaraj
Nidhi Basavaraj
GSGuljabin Sultana
Guljabin Sultana
RJRawnak Jahan
Rawnak Jahan
DZDeeba Zubair
Deeba Zubair
Postpartum hemorrhage (PPH) remains a leading contributor in maternal illness and death worldwide, and its incidence continues to rise. This has led to an increased reliance on allogeneic blood transfusions (ABT), which are limited in supply and carry significant health risks. Cell salvage (CS), which collects and transfuses a patient’s own blood, has been proposed as a useful adjunct or alternative. This narrative review aims to evaluate and summarize the current literature on obstetric CS (OCS) in the management of PPH, with a focus on efficacy, safety, cost-effectiveness, and future research considerations. A literature search was performed using PubMed and Google Scholar, leading to the selection and review of 32 original articles published from 2015 onward. Single case reports, meta-analyses, and other review articles were excluded to minimize amplification bias and ensure an authentic analysis of primary research data. OCS has been shown to reduce the need for donor blood, especially during high-risk cesarean sections, including those with placenta previa and placenta accreta spectrum. Reported benefits include improved maternal hemoglobin, reduced transfusion-related complications, and shorter hospital stay. However, not all the results were statistically significant for reductions in allogeneic transfusion rates. Safety concerns associated with the use of OCS, including amniotic fluid embolism, sepsis, hemolysis, coagulopathy, and Rh alloimmunization, have been substantially addressed through advancements in technology, the implementation of leukocyte depletion filters, and the routine administration of anti-D prophylaxis. Evidence for its use in vaginal deliveries remains sparse, though early studies suggest technical feasibility. Cost-effectiveness is debated and appears dependent on institutional protocols, case volume, and technique optimization. OCS represents a safe and valuable blood-conservation strategy in obstetric practice, particularly for high-risk cesarean section. Wider adoption requires standardized protocols, staff training, and further multicenter research to clarify its role, especially in vaginal deliveries.

21 November 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SILVIA D'IPPOLITOSILVIA D'IPPOLITO
SILVIA D'IPPOLITO
Tina PasciutoTina Pasciuto
Tina Pasciuto
CGChiara Granieri
Chiara Granieri
Sara GiulianoSara Giuliano
Sara Giuliano
GBGreta Barbaro
Greta Barbaro
Nicoletta Di SimoneNicoletta Di Simone
Nicoletta Di Simone
Introduction: Medical treatment with misoprostol represents one of the main treatments for Early Pregnancy Loss (EPL). In our study, we aimed to identify clinical features associated with a successful response to this approach. Methods: A prospective single-center observational study was conducted at the EPL Clinic of the Department of Obstetrics and Gynecology, Fondazione A. Gemelli IRCCS Rome, Italy. Patients were categorized according to the type of treatment received: spontaneous delivery, elective dilatation and curettage, or medical treatment. A separate analysis was performed within the medical treatment group to distinguish women with a successful response from those with an unsuccessful one. The success of medical treatment was calculated as the response rate (number of patients who successfully responded to treatment/total number of treated patients) with a 95% Confidence Interval (CI). For patients undergoing misoprostol treatment, a multivariable analysis was planned to identify predictors of a successful response, including variables with a p value less than 0.05 in the univariable analysis. Receiver Operating Characteristic (ROC) analysis was performed to evaluate the predictive ability of continuous obstetrics parameters for medical treatment success. The optimal cut-off value to differentiate responsive from unresponsive patients was also determined. The significance level was set at p < 0.05. Results: Sixty-four patients who underwent medical treatment were analyzed. Amenorrhea age was the only parameter inversely associated with treatment success, indicating that an earlier amenorrhea age correlated with a better response to misoprostol. ROC analysis identified a cut-off of 62.5 days, with an AUC (95% CI) of 0.72 (0.55–0.89). An amenorrhea age of ≤ 62.5 days predicted a successful response to medical treatment with a specificity (95% CI) of 90.0% (89.8–90.2) and sensitivity (95% CI) of 54.9% (41.2–68.6). Conclusions: Amenorrhea age emerged as a potential predictor of treatment response in women with EPL undergoing misoprostol therapy. However, further studies of larger sample sizes are needed to validate and improve our model.

3 August 2026 in Pregnancy
Verified
Journal Article
Open access
PDF file
ZDZakaria Doughan
Zakaria Doughan
YBYossi Bart
Yossi Bart
JHJoe Haydamous
Joe Haydamous
LDLaura Diab
Laura Diab
Sara GiulianoSara Giuliano
Sara Giuliano
BSBaha M. Sibai
Baha M. Sibai
Background: Expectant management of early‐onset preeclampsia with severe features (<34 weeks’ gestation) requires close maternal surveillance. Although serial testing is routinely performed, recommendations regarding testing frequency vary across professional societies and the clinical utility and financial impact of frequent testing during expectant management remain uncertain. Objective: To describe the role of serial blood tests in guiding delivery decision‐making in preeclampsia with severe features, and to assess the health costs of these serial blood tests. Study Design: A retrospective cohort study of singleton pregnancies diagnosed with preeclampsia with severe features between 23 and 33 weeks at a level IV academic maternity center. Patients with contraindications to expectant management were excluded. Delivery indications were categorized by the contribution of blood test abnormalities: no abnormal blood tests contributing to delivery; blood test abnormalities detected once the decision for delivery was made, but not indication for delivery; and blood test abnormalities as the indication for delivery. Primary outcome was delivery prompted by abnormal blood test findings. Secondary outcomes included charges associated with serial testing. Data analysis included percent with 95% confidence intervals (CIs) or median with interquartile ranges (IQRs). Results: A total of 370 patients met inclusion criteria. Only five (1.4%; 95% CI, 0.4–3.1) had abnormal blood test values (transaminitis and/or thrombocytopenia) prompting delivery decisions, all appearing within 4 days of admission. Abnormal blood testing was not an indication for delivery for most patients ( N = 325; 87.8%; 95% CI, 84.1–91.0). For 40 patients (10.8%; 95% CI, 7.8–14.4), blood test abnormalities were detected after decision for delivery was made. The median number of blood tests per patient was 10 (IQR 6–14), and blood testing charge per patient was $5030 (IQR 3018–7042). The total charge for blood testing was $2.176 million over the study period. Conclusion: Among 370 patients with early‐onset preeclampsia with severe features managed expectantly, only 1% of the cohort had blood test abnormalities as the sole indication for delivery. All other patients were delivered either because of maternal‐fetal indications or developed blood test abnormalities occurring in association with other indications for delivery. Finally, serial blood testing in this setting resulted in total charges of $2.176 million over 9 years. Based on this large cohort, there is a need to reconsider the frequency of blood testing in the absence of new‐onset symptoms or worsening severe features.